Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?

M. Doğan,G. Erdem,N. Zengi̇n
DOI: https://doi.org/10.7314/APJCP.2015.16.14.6167
2015-09-02
Asian Pacific Journal of Cancer Prevention
Abstract:Prostate cancer is common all around the world. Hormonal therapy is the mainstay of therapy, however castration-resistant prostate cancer (CRPC) becomes a serious problem and needs further clinical trials with novel agents. Novel agents like cabazitaxel, abireterone acetate or enzalutamide are encouraging but we do not know which one is the best in metastatic CRPC. In here, treatment modalities for metastatic CRPC are discussed witha mini-review of the literature.
What problem does this paper attempt to address?